Vir Biotechnology Inc (VIR)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	1,590,240	1,675,080	1,810,210	1,970,760	2,077,960	2,149,860	1,952,010	2,001,010	1,431,850	876,274	737,325	650,951	716,852	812,355	563,779	380,333	423,942	-280,797
Debt-to-equity ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,590,240K
= 0.00

Based on the data provided for Vir Biotechnology Inc, the debt-to-equity ratio has consistently been reported as 0.00 for each quarter over the past two years. A debt-to-equity ratio of 0.00 indicates that the company has no debt relative to its equity during those periods. This suggests that Vir Biotechnology is primarily funded through equity rather than debt. While a low or zero debt-to-equity ratio is generally considered favorable as it signifies lower financial risk and potential for financial distress, it is important to note that a completely debt-free capital structure may also limit the company's ability to leverage debt financing for potential growth opportunities. Furthermore, a zero debt-to-equity ratio could indicate that the company may not be taking advantage of potentially cheaper debt capital for expansion or investments. Overall, further analysis of the company's capital structure and financial strategy would be needed to fully assess the implications of its consistent zero debt-to-equity ratio.